---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-24-000045"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2024-08-28T23:59:59+00:00"
generated_at: "2026-05-31T07:12:00.166560+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jeune Aesthetics reports positive Phase 1 interim results for KB301 in wrinkles; plans Phase 2 for décolleté

## Summary
- 94% of décolleté subjects had ≥1-point improvement on GAIS at two months; 89% reported improved wrinkle satisfaction.
- 75% of lateral canthal subjects had ≥1-point improvement on GAIS at two months; 67% reported improved satisfaction.
- No drug-related serious adverse events; adverse events were mild-to-moderate and transient.
- Phase 2 study for dynamic wrinkles of the décolleté expected to start next year; FDA meeting planned.
- Improvements also seen in crepiness, hydration, and radiance in both cohorts.

## SEC filing metadata
- accession: 0001711279-24-000045
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2024-08-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127924000045/0001711279-24-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127924000045/krys-20240828.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-24-000045
- JSON: https://secwatch.observer/filing/0001711279-24-000045.json
- Plain text: https://secwatch.observer/filing/0001711279-24-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.